|
1
|
Eaden JA, Abrams KR and Mayberry JF: The
risk of colorectal cancer in ulcerative colitis: a meta-analysis.
Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eaden J: Review article: colorectal
carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther.
20(Suppl 4): 24–30. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ekbom A, Helmick C, Zack M and Adami HO:
Ulcerative colitis and colorectal cancer. A population-based study.
N Engl J Med. 323:1228–1233. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Canavan C, Abrams KR and Mayberry J:
Meta-analysis: colorectal and small bowel cancer risk in patients
with Crohn’s disease. Aliment Pharmacol Ther. 23:1097–1104. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gillen CD, Walmsley RS, Prior P, et al:
Ulcerative colitis and crohn’s disease: a comparison of the
colorectal cancer risk in extensive colitis. Gut. 35:1590–1592.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Isaacs KL, Lewis JD, Sandborn WJ, et al:
State of the art: IBD therapy and clinical trials in IBD. Inflamm
Bowel Dis. 11(Suppl l): S3–S12. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaser A and Tilg H: Novel therapeutic
targets in the treatmentof IBD. Expert Opin Ther Targets.
12:553–563. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hanauer SB: Inflammatory bowel disease. N
Engl J Med. 334:841–848. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bensoussan M, Jovenin N, Garcia B, et al:
Complementary and alternative medicine use by patients with
inflammatory bowel disease: results from a postal survey.
Gastroenterol Clin Biol. 30:14–23. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stickel F and Schuppan D: Herbal medicine
in the treatment of liver diseases. Dig Liver Dis. 39:293–304.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Treasure J: Herbal medicine and cancer: an
introductory overview. Semin Oncol Nurs. 21:177–183. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Langmead L and Rampton DS: Review article:
complementary and alternative therapies for inflammatory bowel
disease. Aliment Pharmacol Ther. 23:341–349. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
MacDonald TT, Hutchings P, Choy MY, et al:
Tumour necrosis factor-alpha and interferon-gamma production
measured at the single cell level in normal and inflamed human
intestine. Clin Exp Immunol. 81:301–305. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gross V, Andus T, Caesar I, et al:
Evidence for continous stimulation of interleukin-6 production in
Crohn’s disease. Gastroenterology. 102:514–519. 1992.PubMed/NCBI
|
|
15
|
Holub MC, Makó E, Dévay T, et al:
Increased interleukin-6 levels, interleukin-6 receptor and gp130
expression in peripheral lymphocytes of patients with inflammatory
bowel disease. Scand J Gastroenterol Suppl. 228:47–50.
1998.PubMed/NCBI
|
|
16
|
Reinecker HC, Steffen M, Witthoeft T, et
al: Enhanced secretion of tumour necrosis factor-alpha, IL-6, and
IL-1 beta by isolated lamina propria mononuclear cells from
patients with ulcerative colitis and Crohn’s disease. Clin Exp
Immunol. 94:174–181. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mitsuyama K, Sasaki E, Toyonaga A, et al:
Colonic mucosal interleukin-6 in inflammatory bowel disease.
Digestion. 50:104–111. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carey R, Jurickova I, Ballard E, et al:
Activation of an IL-6:STAT3-dependent transcriptome in
pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis.
14:446–457. 2008. View Article : Google Scholar :
|
|
19
|
Ishiguro Y: Mucosal proinflammatory
cytokine production correlates with endoscopic activity of
ulcerative colitis. J Gastroenterol. 34:66–74. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
ter Steege JC, van de Ven MW, Forget PP,
et al: The role of endogenous IFN-gamma, TNF-alpha and IL-10 in
LPS-induced nitric oxide release in a mouse model. Cytokine.
10:115–123. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lawrence T, Willoughby DA and Gilroy DW:
Anti-inflammatory lipid mediators and insights into the resolution
of inflammation. Nat Rev Immunol. 2:787–795. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Turini ME and DuBois RN: Cyclooxygenase-2:
a therapeutic target. Annu Rev Med. 53:35–57. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moncada S: Nitric oxide: discovery and
impact on clinical medicine. J R Soc Med. 92:164–169.
1999.PubMed/NCBI
|
|
24
|
Mudter J, Weigmann B, Bartsch B, et al:
Activation pattern of signal transducers and activators of
transcription (STAT) factors in inflammatory bowel diseases. Am J
Gastroenterol. 100:64–72. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Musso A, Dentelli P, Carlino A, et al:
Signal transducers and activators of transcription 3 signaling
pathway: an essential mediator of inflammatory bowel disease and
other forms of intestinal inflammation. Inflamm Bowel Dis.
11:91–98. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kubo M, Hanada T and Yoshimura A:
Suppressors of cytokine signaling and immunity. Nat Immunol.
4:1169–1176. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alexander WS and Hilton DJ: The role of
suppressors of cytokine signaling (SOCS) proteins in regulation of
the immune response. Annu Rev Immunol. 22:503–529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grutkoski PS, Chen Y, Chung CS and Ayala
A: Sepsis-induced SOCS-3 expression is immunologically restricted
to phagocytes. J Leukoc Biol. 74:916–922. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Corvinus FM, Orth C, Moriggl R, et al:
Persistent STAT3 activation in colon cancer is associated with
enhanced cell proliferation and tumor growth. Neoplasia. 7:545–555.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mitsuyama K, Matsumoto S, Rose-John S, et
al: STAT3 activation via interleukin 6 trans-signalling contributes
to ileitis in SAMP1/Yit mice. Gut. 55:1263–1269. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Isomoto H, Mott JL, Kobayashi S, et al:
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to
SOCS-3 epigenetic silencing. Gastroenterology. 132:384–396. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang XY and Tian DL: Etiological and
pathological characteristics of ulcerative colitis and TCM
differentiation and treatment. Beijing Zhong Yi Yao Da Xue Xue Bao.
30:554–559. 2007.In Chinese.
|
|
33
|
Gong YP, Liu W, Ma GT, et al: Randomized
control study of ‘Qingchang Suppository’ on ulcerative colitis.
Shanghai Zhong Yi Yao Da Xue Xue Bao. 21:33–36. 2007.In
Chinese.
|
|
34
|
Fu NL and Huang JY: Progress of clinical
research of traditional Chinese medicine for the treatment of
ulcerative colitis. J Tradit Chin Med. 40:501–503. 1999.In
Chinese.
|
|
35
|
Li QG: An idea about treatment of
ulcerative colitis by TCM methods. Beijing Zhong Yi. 23:149–150.
2004.In Chinese.
|
|
36
|
Wang CH, Gao WY, Li YF, et al: Study of
Fufangkushen colon-release capsule on ulcerative colitis of
endo-retention of damp heat type. Xian Dai Zhong Xi Yi Jie He Za
Zhi. 18:13–15. 2009.In Chinese.
|
|
37
|
Chen JT, Ke X, Fu XY, et al: The clinical
study of heat-clearing and damp-drying on the treatment of
damp-heat ulcerative colitis. Zhongguo Zhong Xi Yi Jie He Xiao Hua
Za Zhi. 17:256–257. 2009.In Chinese.
|
|
38
|
Ke X, Zhou F, Gao Y, Xie B, et al: Qing
Hua Chang Yin exerts therapeutic effects against ulcerative colitis
through the inhibition of the TLR4/NF-κB pathway. Int J Mol Med.
32:926–930. 2013.PubMed/NCBI
|
|
39
|
Ke X, Chen J, Zhang X, et al: Qing Hua
Chang Yin attenuates lipopolysaccharide-induced inflammatory
response in human intestinal cells by inhibiting NF-κB activation.
Exp Ther Med. 6:189–193. 2013.PubMed/NCBI
|
|
40
|
Levy DE and Darnell J: Stats:
transcriptional control and biological impact. Nat Rev Mol Cell
Biol. 3:651–662. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Murray PJ: The JAK-STAT signaling pathway:
input and output integration. J Immunol. 178:2623–2629. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pfitzner E, Kliem S, Baus D and Litterst
M: The role of STATs in inflammation and inflammatory diseases.
Curr Pharm Des. 10:2839–2850. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Okugawa S, Ota Y, Kitazawa T, et al: Janus
kinase 2 is involved in lipopolysaccharide-induced activation of
macrophages. Am J Physiol Cell Physiol. 285:C399–C408. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhu Z, Jin H, Yu P, et al: Mollugin
inhibits the inflammatory response in LPS-stimulated RAW264.7
macrophages by blocking the Janus kinase (JAK)-signal transducers
and activators of transcription. Biol Pharm Bull. 36:399–406. 2013.
View Article : Google Scholar
|
|
45
|
Greenhalgh CJ, Miller ME, Hilton DJ, et
al: Suppressors of cytokine signaling: Relevance to
gastrointestinal function and disease. Gastroenterology.
123:2064–2081. 2002. View Article : Google Scholar : PubMed/NCBI
|
